Search
KD7040
go.drugbank.com/drugs/DB05214InvestigationalIt is being developed by Kalypsys. … KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.
Vilamakitug
go.drugbank.com/drugs/DB18978InvestigationalVilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic
Diclofenac etalhyaluronate
go.drugbank.com/drugs/DB20937ExperimentalDiclofenac etalhyaluronate is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Diclofenac etalhyaluronate is a anti-inflammatory agent, ibufenac derivative. … Diclofenac etalhyaluronate has a monoisotopic molecular weight of 1475.39 Da.
CR665
go.drugbank.com/drugs/DB05155ExperimentalPreclinical animal studies suggest that CR665 is a potent analgesic compound. … CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists.
Radotinib
go.drugbank.com/drugs/DB12323InvestigationalRadotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Dacetuzumab
go.drugbank.com/drugs/DB12589InvestigationalIt is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Tuparstobart
go.drugbank.com/drugs/DB19118InvestigationalTuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS
Fluorfenidine F-18
go.drugbank.com/drugs/DB19557ExperimentalFluorfenidine F-18 is a small molecule drug. The usage of the INN stem '-nidine' in the name indicates that Fluorfenidine F-18 is a a2 adrenoreceptor agonist. … Fluorfenidine F-18 has a monoisotopic molecular weight of 382.07 Da.
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.